425: NLS Pharmaceutics Advances Merger with Kadimastem, Eyes Nasdaq Listing and Pipeline Expansion

NLS Pharmaceutics provides an update on its strategic merger with Kadimastem, progress in diabetes and neurodegenerative disease treatments, and financial stability.

Summary

• NLS Pharmaceutics has issued a letter to shareholders outlining progress and strategic milestones.
• A definitive merger agreement with Kadimastem Ltd., announced in November 2024, aims to create a Nasdaq-traded biotechnology company.
• Kadimastem's shareholders have voted in favor of the merger, and NLS's major shareholders holding approximately 40% of common shares have signed support letters.
• The merger is anticipated to close in the second quarter of 2025, pending regulatory and shareholder approvals.
• A Registration Statement on Form F-4 has been filed with the SEC, and an application has been submitted to list the merged company on Nasdaq under the name NucelX Ltd. with the ticker NCEL.
• Kadimastem has completed a pre-IND meeting with the FDA for iTOL-102, a potential therapy for Type 1 Diabetes, in collaboration with iTolerance Inc.
• Post-merger, NLS plans to initiate a Phase IIa multi-site clinical trial of AstroRx, Kadimastem's product candidate for ALS.
• NLS has launched a preclinical program evaluating Mazindol ER as a treatment for fentanyl dependence.
• The company raised approximately $4.2 million through private placements in October and December 2024.
• NLS believes this has extended their operational runway to approximately 18 months.
• NLS carries zero long-term debt.

Sentiment

Score: 8

Explanation: The document expresses a positive outlook due to the merger progress, advancements in clinical programs, and financial stability.

Positives

• The merger with Kadimastem is progressing, with shareholder support and regulatory filings underway.
• The combined company will have a robust portfolio of advanced therapies.
• Kadimastem's diabetes treatment, iTOL-102, has achieved a pre-IND meeting with the FDA.
• NLS plans to initiate a Phase IIa trial for AstroRx in ALS post-merger.
• NLS has a strong financial position with no long-term debt.
• The company has extended its operational runway to approximately 18 months through recent private placements.
• NLS is expanding its pipeline with a preclinical program for fentanyl dependence.

Risks

• The merger is subject to regulatory and shareholder approvals, and customary closing conditions.
• Clinical trials may encounter delays or obstacles.
• Products may not be approved by regulatory agencies.
• Scientific difficulties may arise with the products being advanced.
• Products may be more expensive than anticipated.
• Results in the laboratory may not translate to equally good results in real clinical settings.
• Results of preclinical studies may not correlate with the results of human clinical trials.
• The company's patents may not be sufficient.
• Products may harm recipients.
• Changes in legislation may adversely impact the company.
• Inability to timely develop and introduce new technologies, products and applications.
• Loss of market share and pressure on pricing resulting from competition.

Future Outlook

NLS Pharmaceutics aims to capitalize on emerging opportunities within the biotechnology landscape, build a strong international pipeline, deliver life-changing therapies, expand through innovation and collaborations, and maximize shareholder value by maintaining a strong financial position.

Management Comments

• We are thrilled to share the significant progress and strategic milestones NLS Pharmaceutics has achieved, positioning our company for a transformative future in the biotechnology sector.
• We believe that these developments underscore the sectors robust growth and the immense potential it holds for innovative treatments.

Industry Context

The document highlights the growth in the diabetes treatment landscape, referencing Novo Nordisk's acquisition of Inversago Pharma and Roche's acquisition of Carmot Therapeutics, indicating a strategic emphasis on developing novel therapies for obesity, diabetes, and related metabolic disorders. Sana Biotechnology's advancements in diabetes are also mentioned.

Comparison to Industry Standards

• The document references Novo Nordisk's acquisition of Inversago Pharma for up to $1.075 billion and Roche's acquisition of Carmot Therapeutics for $2.7 billion, indicating the high value placed on innovative diabetes treatments.
• Sana Biotechnology's advancements in diabetes are also mentioned, positioning them as a potential leader in developing transformative treatments for type 1 diabetes.

Stakeholder Impact

• Shareholders will benefit from the creation of a Nasdaq-traded biotechnology company with a robust portfolio.
• Patients may benefit from the development of innovative therapies for CNS disorders, diabetes, ALS, and fentanyl dependence.
• The company's employees will be part of a larger, more diversified organization.

Next Steps

• Closing the merger with Kadimastem in the second quarter of 2025.
• Listing the merged company on Nasdaq under the ticker NCEL.
• Initiating a Phase IIa multi-site clinical trial of AstroRx for ALS post-merger.
• Advancing the preclinical program for Mazindol ER as a treatment for fentanyl dependence.
• Poster presentation at the American Society of Clinical Psychopharmacologys 2025 Annual Meeting.

Key Dates